The performance of F-PSMA PET/CT in the detection of prostate cancer: a systematic review and meta-analysis.

This paper presents a meta-analysis regarding the detection rate (DR) of fluorine-18 (F)-labeled prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) in the management of patients with prostate cancer (PCa). Relevant studies regarding F-PSMA PET/CT in the management of PCa published until June 1, 2021, were electronically searched in online databases including EMBASE, PubMed, and Web of Science. The primary outcome was the DR of F-PSMA PET/CT in managing PCa patients, while the secondary outcome was the DR of F-PSMA PET/CT according to Gleason scores and serum prostate-specific antigen (PSA) level.